•Rayner partners with Promptly to integrate Eyejourney into US clinic software •SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System•I-C eye drops ease mild-to-moderate dry eye in early trial•Eclipse reports positive phase 2 topline data on DME steroid implant•OCT biomarkers may predict DME treatment response•Rayner partners with Promptly to integrate Eyejourney into US clinic software •SpyGlass Pharma reports 4-year, FIH data on BIM-IOL System•I-C eye drops ease mild-to-moderate dry eye in early trial•Eclipse reports positive phase 2 topline data on DME steroid implant•OCT biomarkers may predict DME treatment response
HEADLINES
FEATURED
Phase 1/2 clinical trial expected to kick off before the end of the year to evaluate OPGx-RDH12’s potential in treating inherited childhood blindness.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
